vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -83.0%, a 122.4% gap on every dollar of revenue.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
RYTM vs SLNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $66.0M |
| Net Profit | $-47.5M | $26.0M |
| Gross Margin | 91.6% | 98.3% |
| Operating Margin | -82.2% | 33.5% |
| Net Margin | -83.0% | 39.4% |
| Revenue YoY | 36.9% | — |
| Net Profit YoY | -9.6% | 134.0% |
| EPS (diluted) | $-0.73 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | — | ||
| Q3 25 | $51.3M | $66.0M | ||
| Q2 25 | $48.5M | $32.7M | ||
| Q1 25 | $32.7M | — | ||
| Q4 24 | $41.8M | — | ||
| Q3 24 | $33.3M | — | ||
| Q2 24 | $29.1M | — | ||
| Q1 24 | $26.0M | — |
| Q4 25 | $-47.5M | — | ||
| Q3 25 | $-52.9M | $26.0M | ||
| Q2 25 | $-46.6M | $-4.7M | ||
| Q1 25 | $-49.5M | — | ||
| Q4 24 | $-43.3M | — | ||
| Q3 24 | $-43.6M | — | ||
| Q2 24 | $-32.3M | — | ||
| Q1 24 | $-141.4M | — |
| Q4 25 | 91.6% | — | ||
| Q3 25 | 89.3% | 98.3% | ||
| Q2 25 | 88.6% | 97.9% | ||
| Q1 25 | 88.8% | — | ||
| Q4 24 | 90.9% | — | ||
| Q3 24 | 88.5% | — | ||
| Q2 24 | 89.9% | — | ||
| Q1 24 | 89.2% | — |
| Q4 25 | -82.2% | — | ||
| Q3 25 | -102.6% | 33.5% | ||
| Q2 25 | -93.4% | -20.0% | ||
| Q1 25 | -143.7% | — | ||
| Q4 24 | -98.6% | — | ||
| Q3 24 | -132.0% | — | ||
| Q2 24 | -139.2% | — | ||
| Q1 24 | -538.7% | — |
| Q4 25 | -83.0% | — | ||
| Q3 25 | -103.1% | 39.4% | ||
| Q2 25 | -96.1% | -14.4% | ||
| Q1 25 | -151.4% | — | ||
| Q4 24 | -103.6% | — | ||
| Q3 24 | -131.2% | — | ||
| Q2 24 | -110.9% | — | ||
| Q1 24 | -544.4% | — |
| Q4 25 | $-0.73 | — | ||
| Q3 25 | $-0.82 | $0.47 | ||
| Q2 25 | $-0.75 | $-0.09 | ||
| Q1 25 | $-0.81 | — | ||
| Q4 24 | $-0.71 | — | ||
| Q3 24 | $-0.73 | — | ||
| Q2 24 | $-0.55 | — | ||
| Q1 24 | $-2.35 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $494.8M |
| Total Assets | $480.2M | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | — | ||
| Q3 25 | $416.1M | $498.9M | ||
| Q2 25 | $291.0M | $286.8M | ||
| Q1 25 | $314.5M | — | ||
| Q4 24 | $320.6M | — | ||
| Q3 24 | $298.4M | — | ||
| Q2 24 | $319.1M | — | ||
| Q1 24 | $201.2M | — |
| Q4 25 | $139.1M | — | ||
| Q3 25 | $148.8M | $494.8M | ||
| Q2 25 | $-11.9M | $240.1M | ||
| Q1 25 | $18.9M | — | ||
| Q4 24 | $21.7M | — | ||
| Q3 24 | $11.2M | — | ||
| Q2 24 | $39.3M | — | ||
| Q1 24 | $61.6M | — |
| Q4 25 | $480.2M | — | ||
| Q3 25 | $506.9M | $599.9M | ||
| Q2 25 | $372.7M | $332.3M | ||
| Q1 25 | $386.7M | — | ||
| Q4 24 | $392.3M | — | ||
| Q3 24 | $363.6M | — | ||
| Q2 24 | $381.8M | — | ||
| Q1 24 | $258.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $43.5M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 65.8% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | — | ||
| Q3 25 | $-26.6M | $43.5M | ||
| Q2 25 | $-23.3M | $-12.6M | ||
| Q1 25 | $-40.4M | — | ||
| Q4 24 | $-18.8M | — | ||
| Q3 24 | $-25.2M | — | ||
| Q2 24 | $-29.1M | — | ||
| Q1 24 | $-40.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $43.5M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 65.8% | ||
| Q2 25 | — | -38.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
